In a report released on February 3, Robyn Karnauskas from Truist Financial reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $91.00. The company’s shares closed last Friday at $84.50.
Karnauskas covers the Healthcare sector, focusing on stocks such as Biogen, BioMarin Pharmaceutical, and Fate Therapeutics. According to TipRanks, Karnauskas has an average return of 9.0% and a 53.38% success rate on recommended stocks.
In addition to Truist Financial, Gilead Sciences also received a Buy from Piper Sandler’s Do Kim in a report issued on February 3. However, on the same day, Bank of America Securities maintained a Hold rating on Gilead Sciences (NASDAQ: GILD).
See today’s best-performing stocks on TipRanks >>
GILD market cap is currently $106B and has a P/E ratio of 23.20.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GILD in relation to earlier this year. Most recently, in November 2022, Diane Wilfong, the SVP, Controller & CAO of GILD sold 6,416.00 shares for a total of $535,736.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1987, California-based Gilead Sciences, Inc. is a biopharmaceutical company, which focuses on the research, development, and commercialization of antiviral drugs used in the treatment of diseases like human immunodeficiency virus (HIV), hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi. It offers its products under brands including Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi.
Read More on GILD:
- Gilead announces FDA approves Trodelvy in pre-treated HR+/HER2- breast cancer
- Gilead price target raised to $80 from $69 at Baird
- Gilead price target raised to $112 from $111 at Piper Sandler
- Gilead raises quarterly dividend 2.7% to 75c per share
- Gilead sees FY23 adjusted EPS $6.60-$7.00, consensus $6.73
